Pharmacy & Therapeutics - February 2008 - (Page 64)

CONTENTS Cover: Blood clot, scanning electron micrograph. Red blood cells, platelets (green), and a white blood cell (yellow) are enmeshed in the clot. Mag.: x4,200 at 6 x 7 cm; x2,100 at 35 mm. See related articles on pages 98 and 107. (Credit: CNRI / Photo Researchers, Inc.) February 2008 FEATURES EDITOR’S MEMO DEPARTMENTS Editorial 69 David Nash, MD, MBA, discusses the challenges and benefits of “mobile social networking” in the digital age of constant connectedness and its potential effect on the future of medicine. Medication Errors 70 Matthew Grissinger, RPh, FASCP, reports on the problems involved when lidocaine is added to IV potassium chloride. Prescription: Washington 73 Stephen Barlas details the problems that might arise if drug manufacturers are permitted to market drugs for off-label purposes, especially antipsychotic agents, and the concerns of Congress that clinical trials will be lacking to support the new indications. New Drugs/Drug News/ New Medical Devices 76 From aliskiren to Welchol, P&T presents the latest information on FDA approvals, indications, and industry updates. Drug Forecast 92 Authors Cromer and Peker review aliskiren (Tekturna) for hypertension. The Language of (Forgive Us) Change, As P&T Enters the Digital Age We know you’re as sick of the word “change” as we are, but like many clichés, it serves its purpose. Oh, and by the way, P&T is going digital. Sonja Sherritze 74 Use and Outcomes of Antifibrinolytic Therapy in Patients Undergoing Cardiothoracic Surgery at 20 Academic Medical Centers in the United States 98 Given the association between the use of aprotinin (Trasylol) and an increased risk of adverse events among cardiothoracic surgery patients, in contrast to a lack of elevated risk for aminocaproic acid and tranexamic acid, the authors suggest that hospitals examine their current patterns of use and perhaps restrict aprotinin for these patients to prevent major blood loss. Karl Matuszewski, MS, PharmD; Robert Schoenhaus, PharmD; Mary Ellen Bonk, PharmD; James Lane, PharmD; and Michael Oinonen, PharmD, MPH Evaluation of the Management of Acute Venous Thromboembolism and Its Outcomes: One Institution’s Experience The authors describe a study in which they sought to determine whether standard practice guidelines for the care of patients with VTE were being followed at their VA center. Cristin Williams, PharmD, Ji Koo, PharmD, and Jonathan Hass, PharmD MEETING HIGHLIGHTS 107 American Society of Hematology, 49th Annual Meeting Presentations cover lenalidomide (Revlimid) in the treatment of multiple myeloma, eculizumab (Soliris) for paroxysmal nocturnal hemolysis, RAD001 (Everolimus) for lymphoma, the use of deferasirox (Exjade) in patients with iron overload, and dasatinib (Sprycel) and nilotinib (Tasigna) for chronic myelogenous leukemia. Walter Alexander 111 Pharmaceutical Approval Update Topics include sapropterin dihydrochloride tablets (Kuvan) for reducing phenylalanine levels in patients with phenylketonuria; nebivolol (Bystolic) for hypertension; and a starch infusion (Voluven) to prevent decreased blood volume during surgery. Marvin M. Goldenberg, PhD, RPh, MS 114 64 P&T® • February 2008 • Vol. 33 No. 2

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - February 2008

Pharmacy & Therapeutics - February 2008 Contents Editorial Medication Errors Prescription: Washington The Language of (Forgive Us) Change, As P&T Enters the Digital Age New Drugs/Drug News/New Medical Devices Drug Forecast Use and Outcomes of Antifibrinolytic Therapy in Patients Undergoing Cardiothoracic Surgery at 20 Academic Medical Centers in the United States Evaluation of the Management of Acute Venous Thromboembolism and Its Outcomes: One Institution's Experience American Society of Hematology, 49th Annual Meeting Pharmaceutical Approval Update

Pharmacy & Therapeutics - February 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.